Venus Medtech (Hangzhou) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VMTHF research report →
Price Chart
About the company
Venus Medtech (Hangzhou) Inc. , together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis.
- CEO
- Hou-Sen Lim
- IPO
- 2021
- Employees
- 560
- HQ
- Hangzhou, WA, CN
Get TickerSpark's AI analysis on VMTHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $186.06M
- P/E
- -0.92
- PEG
- -0.05
- P/S
- 1.68
- P/B
- 0.28
- EV/EBITDA
- -2.17
- Div Yield
- 0.00%
- Gross Margin
- 53.10%
- Op Margin
- -148.84%
- Net Margin
- -181.92%
- ROE
- -28.24%
- ROIC
- -18.41%
Latest fiscal year · YoY change
- Revenue
- $298.87M-36.5%
- Gross Profit
- $137.04M-62.7%
- Op Income
- $-337,177,361
- Net Income
- $-397,172,134+44.4%
- EPS
- $-0.91+44.2%
- OCF Growth
- -1453.7%
- FCF Growth
- -1764.0%
- 52W High
- $0.52
- 52W Low
- $0.27
- 50D MA
- $0.42
- 200D MA
- $0.40
- Beta
- 1.15
- RSI (14)
- 98
- Avg Volume
- 656
No earnings-call transcripts are available for VMTHF yet.
- Free Float
- 89.4%
- Shares Outstanding
- 441.01M
- Float Shares
- 394.36M
Our VMTHF coverage
Recent articles, reports, and earnings notes.
No research on VMTHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VMTHF report →Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
prnewswire.com · Apr 21
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
prnewswire.com · Sep 5
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
prnewswire.com · Jun 14
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
prnewswire.com · Feb 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.